Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹638 Cr
Revenue (TTM)
₹505 Cr
Net Profit (TTM)
₹16 Cr
ROE
13.3 %
ROCE
14.4 %
P/E Ratio
40
P/B Ratio
4.4
Industry P/E
30.75
EV/EBITDA
20.1
Div. Yield
0 %
Debt to Equity
1.3
Book Value
₹5.3
EPS
₹0.7
Face value
1
Shares outstanding
240,658,870
CFO
₹10.07 Cr
EBITDA
₹106.20 Cr
Net Profit
₹46.98 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sudarshan Pharma
| -3.8 | -5.5 | -1.9 | -14.9 | 68.1 | -- | -- |
|
BSE Commodities
| -4.9 | -8.2 | -6.3 | 5.0 | 15.1 | 11.3 | 15.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
Sudarshan Pharma
| -38.1 | 454.4 |
|
BSE Small Cap
| -6.6 | 29.0 |
|
BSE Commodities
| 12.5 | 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sudarshan Pharma
|
26.5 | 638.0 | 505.1 | 16.0 | -- | 13.3 | 40 | 4.4 |
| 408.7 | 14,812.0 | 8,045.0 | 378.0 | 7.8 | 6.6 | 39.2 | 2.5 | |
| 1,103.4 | 14,670.4 | 1,088.6 | 215.8 | 27.4 | 9.8 | 68 | 6.1 | |
| 1,265.4 | 14,401.2 | 2,229.8 | 229.1 | 18.1 | 5.7 | 83.7 | 4.4 | |
| 1,377.7 | 18,790.9 | 7,946.4 | 533.3 | 8.9 | 9.9 | 35.2 | 3.3 | |
| 4,363.3 | 13,350.0 | 2,347.3 | 398.8 | 17.9 | 16.4 | 33.7 | 5.2 | |
| 3,703.4 | 8,600.3 | 2,071.4 | 307.8 | 17.4 | 12.6 | 27.9 | 3.4 | |
| 579.2 | 9,224.0 | 4,260.9 | 265.7 | 9.0 | 9.2 | 34.7 | 3.0 | |
| 2,941.1 | 11,489.3 | 2,455.7 | 286.6 | 18.6 | 25.6 | 38.3 | 8.7 | |
| 1,309.0 | 13,575.5 | 2,271.4 | 442.9 | 24.7 | 15.5 | 30.6 | 4.5 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
2008
Chairman
Hemal Vasantrai Mehta
Managing Director
Hemal Vasantrai Mehta
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Sudarshan Pharma Industries Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Sudarshan Pharma Industries Ltd is ₹26.51 (BSE) as of 02-Apr-2026 IST. Sudarshan Pharma Industries Ltd has given a return of 68.11% in the last 3 years.
The P/E ratio of Sudarshan Pharma Industries Ltd is 39.99 times as on 02-Apr-2026, a 30 premium to its peers’ median range of 30.75 times.
The P/B ratio of Sudarshan Pharma Industries Ltd is 4.43 times as on 02-Apr-2026, a 115 premium to its peers’ median range of 2.06 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.06
|
5.76
|
|
2024
|
1.56
|
1.60
|
|
2023
|
19.08
|
1.33
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Sudarshan Pharma Industries Ltd are Rs 35.19 and Rs 18.50 as of 04-Apr-2026.
Sudarshan Pharma Industries Ltd has a market capitalisation of ₹ 638 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sudarshan Pharma Industries Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹1.11
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.